FindTrial
Sign In

Clinical Application of ECMO(or Ultra-Protective Lung Mechanical Ventilation) in the Treatment of Patients with ARDS due to novel Coronavirus Pneumonia (COVID-19)

Clinical Application of ECMO(or Ultra-Protective Lung Mechanical Ventilation) in the Treatment of Patients with ARDS due to novel Coronavirus Pneumonia (COVID-19)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030744
Enrollment
Unknown
Registered
2020-03-13
Start date
2020-02-01
Completion date
Unknown
Last updated
2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

ECMO group:ECMO therapy
the conventional treatment group:no

Sponsors

Shandong Provincial Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients who were diagnosed as COVID-19 by nucleic acid test; 2. Severe ARDS patients according to the Berlin definition.

Exclusion criteria

Exclusion criteria: 1. Aged<14 years; 2. Accompanied by other serious organ dysfunction (including severe liver and kidney dysfunction, upper gastrointestinal bleeding, DIC, etc.).

Design outcomes

Primary

MeasureTime frame
Inpatient mortality;ICU hospital stay;—

Secondary

MeasureTime frame
Total hospital stay;ICU fatality rate;—

Countries

China

Contacts

Public ContactFenglin Liu

Shandong Provincial Chest Hospital

xkyylfl@163.com+86 13953116564

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026